ClinicalTrials.gg

Program

GV101

A development code.

Its studies are mostly in Friedreich Ataxia, led by Graviton Bioscience.

Furthest: phase 2, since May 13, 20253 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Graviton Bioscience31 open or runningphase 2since May 13, 2025Sep 26, 2021Jul 2027phase 2 · NCT07870590

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2021First study: phase 1 study in Phase 1First studyNCT05068947 · 16 enrolled · United States
  2. May 13, 2025Phase 2 study in Weight ManagementNCT06979505 · 131 enrolled · United States, Israel
  3. Oct 6, 2026Phase 2 study in Friedreich AtaxiaNCT07870590 · 48 planned · United States

Ahead

  1. Jul 2027Primary completion: phase 2 study in Friedreich AtaxiaNCT07870590

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07870590Friedreich Ataxia · United States2Not yet recruitingJul 202748
NCT06979505Weight Management · United States, Israel2CompletedJan 28, 2026131
NCT05068947Phase 1 · United States1CompletedOct 22, 202116

How it is read

Names in the registry

  • “GV101”, 3 entries

Codes read as this program: GV101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.